Company Stock Information

Company Stock Data | Company Summary in Chinese | Company Press Release (34) | NAI Interview(0) | Company Event(0) | Research Report (0) | Chinese Micro Site | Contact Company
ONCOGENEX PHARMACEUTICALS INC (NASDAQ:OGXI)
Show Interactive Chart | Add to Portfolio

Stock Info

Last Trade 2.230
Change 0.000
Change (%) 0%
Volume 356,640
10 Days Avg Vol 328,500
3 Months Avg Vol 1,615,300
52 Weeks Lo/Hi $ 1.74 - $ 3.84
YTD Price Gain % -5.7%
10 Wks Moving Avg $ 2
200 Days Moving Avg $ 2
Liquidity Ratio 106,100
Market Cap 11,658,635

Related News

TitleDate
OncoGenex Pharmaceuticals Announces Appointment of John A. Bencich as Vice President and Chief Financial Officer08/07/2014
OncoGenex Announces Target Number of Events Reached in Phase 3 SYNERGY Trial of Custirsen in Metastatic Castrate-Resistant Prostate Cancer02/10/2014
OncoGenex Announces Update on Phase 3 SYNERGY Trial Evaluating Custirsen in Men with Metastatic Castrate-Resistant Prostate Cancer11/18/2013
OncoGenex Announces that the Rainier™ Clinical Trial Evaluating Apatorsen (OGX-427) in Combination with ABRAXANE® plus Gemcitabine in Patients with Metastatic Pancreatic Cancer is Now Open for Enrollment08/26/2013

Summary

Contact Info

OncoGenex Pharmaceuticals's address OncoGenex Pharmaceuticals
Suite 201 - 19820 North Creek Parkway
Bothell WA 98011
OncoGenex Pharmaceuticals's Telephne number +1 425 686-150
OncoGenex Pharmaceuticals's fax number
OncoGenex Pharmaceuticals's email account sspecht@oncogenex.com
OncoGenex Pharmaceuticals's web site http://www.oncogenex.com
Mr. Scott Cormack